Work package 1 Management and administration

Work package 2 Subject identification and recruitment

Work package 3 Biobank, reprogramming and scale-up

Work package 4 iPSC Differentiation and scale-up

Work package 5 Molecular profiling

Work package 6 Data management and interpretation

Work package 7 Peripheral nervous system

Work package 8 CNS: Neurodegenerative and neurodysfunctional diseases

Work package 9 iPSC Models of diabetes

Work package 10 iPSC Models in drug safety

Work package 11 Assay development

Work package 12 Communication within and between consortia

 

Work package 1 - Management and administration:

The aim of this WP1 is to ensure successful completion of the project. Effective project management is a central element of successful research. Its structure is anchored in the Project Agreement. The management activities give highest priority to meeting the goals of the work plan and ensuring that there are transparent and accountable governance structures in place.

Work package leader:

Martin Graf, F. Hoffmann-La Roche & Dr. Zameel Cader, University of Oxford

 

Work package 2 - Subject identification and recruitment:

Careful selection and characterisation of subjects and recruitment of biomaterials including fibroblasts and keratinocytes lay the ground for all other work packages. WP2 recruits subjects across three disease areas (diseases of the PNS, CNS, and diabetes), patients with specific features of drug response, as well as healthy controls. It also ensures that all clinical and trial data are collated, all biomaterials are collected, and that all ethical, social and legal requirements for the use of human material are fulfilled.

Work package leader:

Prof. Christine Klein, University of Luebeck & Deirdre Newman, University of Oxford

 

Work package 3 - Biobank, reprogramming and scale-up:

The global aim of WP3 is the generation of 1 500 high quality iPSC lines from 500 healthy and diseased subjects selected in WP2. These are banked and used as research tools as described in WP7 to WP10.

Work package leader:

Prof. Lyle Armstrong, University of Newcastle upon Tyne & Dr. Mark Burcin, F. Hoffmann-La Roche

 

Work package 4 - iPSC Differentiation and scale-up:

This work package develops transcriptional and epigenetic profiles conferring cell identity, iPSC/differentiated line tools and iPSC/progenitor cell scale-up technologies.

Work package leader:

Dr. Sally Cowley, University of Oxford & Dr Ines Royaux, Janssen Pharmaceutica NV

 

Work package 5 - Molecular profiling:

This work package focuses on molecular profiling. Molecular profiling, including sequencing, transcriptomic, proteomic and metabolomics profiling is used to characterise patients (WP2), iPS cell lines (WP3-4) and differentiated cells (WP7-10). Furthermore, molecular profiling serves to assess the effect of pharmacological or toxicological intervention.

Work package leader:

Prof. Jerzy Adamski, Helmholtz Zentrum München & Dr. Pieter Peeters, Janssen Pharmaceutica NV & Dr Rory Bowden, University of Oxford

 

Work package 6 - Data management and interpretation:

WP6 provides the genetic and molecular state of each disorder-specific cell line, in many cases over the differentiating cell lineage and/or pre/post treatment challenge, facilitating studies that elucidate these etiopathologies and identify therapeutic opportunities and consequences. WP6 provides a single coherent view, from the genome to metabolome to proteome to phenotype.

Work package leader:

Dr. Caleb Webber, University of Oxford & Dr. Melissa Thomas, Eli Lilly

 

Work package 7 - Peripheral nervous system:

This work package develops standardised protocols for peripheral nervous system differentiation and functional assessment. It also provides a functional characterisation and pharmacology of single cell type models generated from patients with peripheral neuropathies and develops multi-cell type models of PNS disease.

Work package leader:

Dr. Zameel Cader, University of Oxford

 

Work package 8 - CNS: Neurodegenerative and neurodysfunctional diseases:

The aim of WP8 is to provide disease-relevant, human in vitro systems in neurons and glia derived from iPSC generated from well-characterised patients with neurodegenerative (Alzheimer's disease and Parkinson's disease) and neurodysfunctional disorders (autism, schizophrenia, migraine and biploar disorder).

Work package leader:

Dr. Richard Wade-Martins, University of Oxford & Dr. Viktor Lakics, AbbVie Deutschland GmbH & Co. KG

 

Work package 9 - iPSC Models of diabetes:

The overall objective is to provide access to disease-relevant cell types from iPSCs generated from well-characterised patients with diabetes (monogenic, syndromic and type 2). A major focus will involve the pancreatic islet, and the development and implementation of protocols for efficient, reproducible differentiation of iPSCs along the endocrine-cell lineage.

Work package leader:

Prof. Mark McCarthy, University of Oxford & Dr. Mattias Hansson, Nono Nordisk

 

Work package 10 - iPSC Models in drug safety:

The aim of WP10 is to generate functionally mature target cells of toxicological interest from iPSC, in a robust and scalable manner. This WP, in collaboration with WP3, 4, 5, 6, 7, 8, 9 and 11, evaluates iPSC-derived differentiated cell types for toxicology assays. WP10 takes advantage of existing and newly generated iPSC-derived cells and of the vast expertise on toxicological assays and model compounds in the consortium. Cells are differentiated by participants with the specific know-how. For scale-up, and exposure to compounds and assay development, characterized cells are transferred from the generating laboratories to the test facilities of partners with a large expertise in toxicity assay development and toxicity testing. Endpoint measurement will be performed in collaboration with WP5 (molecular profiling) and WP11 (assay development).

Work package leader:

Prof. Jim Ross, University of Edinburgh & Dr. Nicole Clemann, F. Hoffmann-La Roche

 

Work package 11 - Assay development:

Development and optimisation of cell-based assay methods with the iPSC derived cell types either based on existing assay methods and protocols used in the previous WPs or through the development of novel methodology. The developed assays are to be scaled-up and transferred to high-throughput procedures by a close collaboration with EFPIA participants.

Work package leader:

Prof. Carl-Fredrik Mandenius, Linköping University

 

Work package 12 - Communication within and between consortia:

Our objective is to maximise the impact and effectiveness of StemBANCC on drug discovery by seeking to communicate our findings, address the training needs of our participants, and seeking to maximise the influence of our outcome on interested stakeholders in the field. The objectives include to foster communication and dissemination of findings to the public and within the EU portfolio of projects and to coordinate our iPSC work with interested parties and stakeholders internationally.

Work package leader:

Prof. Jack Price, King’s College London